Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy

Publication date: 1 January 2019Source: Colloids and Surfaces B: Biointerfaces, Volume 173Author(s): Abhishesh Kumar Mehata, Shreekant Bharti, Priya Singh, Matte Kasi Viswanadh, Lakshmi Kumari, Poornima Agrawal, Sanjay Singh, Biplob Koch, Madaswamy S. MuthuAbstractBreast cancer, up-regulated with human epidermal growth factor receptor type-2 (HER-2) has led to the concept of developing HER-2 targeted anticancer therapeutics. Docetaxel-loaded D-α-tocopherol polyethylene glycol 1000 succinate conjugated chitosan (TPGS-g-chitosan) nanoparticles were prepared with or without Trastuzumab decoration. The particle size and entrapment efficiency of conventional, non-targeted as well as targeted nanoparticles were in the range of 126–186 nm and 74–78% respectively. In-vitro studies on SK-BR-3 cells showed that docetaxel-loaded non-targeted and HER-2 receptor targeted TPGS-g-chitosan nanoparticles have enhanced the cellular uptake and cytotoxicity with a promising bioadhesion property, in comparison to conventional formulation i.e., Docel™. The IC50 values of non-targeted and targeted nanoparticles from cytotoxic assay were found to be 43 and 223 folds higher than Docel™. The in-vivo pharmacokinetic study showed 2.33, and 2.82-fold enhancement in relative bioavailability of docetaxel for non-targeted and HER-2 receptor targeted nanoparticles, respectively than Docel™. Further, after i.v administration, non-targeted and targeted nanoparticles achieved 3.48 and 5.94 times pr...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research